Relapsing Remitting Multiple Sclerosis: Clinical Trials

1 trial for Relapsing Remitting Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Terminated 1

Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
BG00002 (natalizumab), interferon beta-1a, glatiramer acetate - Relapsing Remitting Multiple Sclerosis
Phase 3TerminatedBiogen842010-03-012014-09-03

Narrower conditions

Multiple Sclerosis, Relapsing-Remitting (1)

Broader conditions

Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)  ·  Multiple Sclerosis (1)  ·  Nervous System Diseases (1)

Interventions

Glatiramer Acetate (1)  ·  Interferon beta-1a (1)  ·  Natalizumab (1)

Sponsors

Biogen (1)

Countries

Australia (1)  ·  Canada (1)  ·  Czechia (1)  ·  Finland (1)  ·  France (1)  ·  Hungary (1)  ·  Italy (1)  ·  Latvia (1)  ·  Poland (1)  ·  Slovenia (1)  ·  Spain (1)  ·  Sweden (1)  ·  United States (1)